🔎 Trials Near Me

Gara Jalqabaatti › Kansarii Ovarii › Maryland

Qorannoo klinikaalii Kansarii Ovarii Maryland keessatti

Qorannoo 40 Kansarii Ovarii f Maryland keessatti hirmaatuu jiru.

Magaalota Maryland keessatti

Takkalaa qorannoo (Ingiliffa)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Walter Reed National Military Medical Center, Bethesda
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 45 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06995898

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • University of Maryland/Greenebaum Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
  • National Institutes of Health Clinical Center, Bethesda
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04847063

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 72 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT01174121

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 3 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT01441089

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 2 hanga 100 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT01950572

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06885697

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Johns Hopkins University, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06172478

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

  • Research Site, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 01-Onk-2026 · NCT07851025

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • University of Maryland, Baltimore /ID# 275308, Baltimore
  • Holy Cross Hospital /ID# 275872, Silver Spring
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ful-2026 · NCT06890338

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 72 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03412877

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Greater Baltimore Medical Center, Baltimore
  • Sinai Hospital Of Baltimore, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • United Theranostics, Glen Burnie
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213791

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Maryland Oncology Hematology (MOH) ( Site 8002), Columbia
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT07318558

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Holy Cross Hospital, Silver Spring
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 15-Ful-2026 · NCT07214779

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Greater Baltimore Medical Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 99 · Dubartoota · Haaromfame 15-Ful-2026 · NCT07023627

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Baltimore
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT05123482

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Holy Cross Hospital, Silver Spring
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 26-Hag-2026 · NCT05281471

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 72 · Saalaa hunda · Haaromfame 13-Hag-2026 · NCT02830724

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Christiana Care - Union Hospital, Elkton
Namoota walitti qabaa jira
Umuriin 35 hanga 50 · Dubartoota · Haaromfame 07-Hag-2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Christiana Care - Union Hospital, Elkton
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Maryland Oncology Hematology, Rockville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Maryland Oncology Hematology - Primary, Columbia
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • The John Hopkins Hospital, Baltimore
  • Maryland Oncology Hematology- Columbia, Rockville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 8 fi ol · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT05503797

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  • University of Maryland, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 14-Ado-2026 · NCT05804370

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Greater Baltimore Medical Center, Towson
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 02-Ado-2026 · NCT06819007

EXoPERT EMERALD Clinical Study

  • John Hopkins University, Baltimore
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 45 fi ol · Saalaa hunda · Haaromfame 01-Ado-2026 · NCT07186296

Integrated Cancer Repository for Cancer Research

  • Northwest Hospital, Randallstown
  • William E. Kahlert Regional Cancer Center, Westminster
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA11-0, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Cam-2026 · NCT06953089

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

  • National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 19-Cam-2026 · NCT06503146

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Bit-2026 · NCT03968406

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT06778863

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Maryland Oncology Hematology, P.A., Annapolis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 23-Mud-2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Baltimore
  • Massive Bio SYNERGY-AI site, Bethesda
  • Massive Bio SYNERGY-AI site, Silver Spring
  • fi 1 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 27-Onk-2025 · NCT06617923

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

  • Anne Arundel Health System, Annapolis
  • Johns Hopkins University School of Medicine, Baltimore
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 30 fi ol · Dubartoota · Haaromfame 16-Ful-2025 · NCT04794322

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

  • Johns Hopkins, Baltimore
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Cam-2025 · NCT04503265

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

  • Holy Cross Hospital, Silver Spring
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Bit-2025 · NCT04196257

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.